ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2754

AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria

Manouk de Hooge1, Ann-Sophie De Craemer 1, Thomas Renson 1, Philippe Carron 1, Liselotte Deroo 1, Dirk Elewaut 1 and Filip Van den Bosch 1, 1Ghent University Hospital, Ghent, Belgium

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, magnetic resonance imaging (MRI) and ankylosing spondylitis (AS)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T089: Imaging of Rheumatic Diseases II (2750–2755)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The modified New York criteria (mNY) combine clinical symptoms with radiographic sacroiliitis on conventional pelvic radiographs (X-SI) classifying radiographic axial SpA patients (r-axSpA). AxSpA is known to typically start in the third era of life but there is a diagnostic delay of ±7 years. As the mNY criteria classify the most typical and severe expression of axSpA it is suggested that the mNY criteria are less useful in younger patients. Purpose of the study is to explore the diagnostic utility of the mNY criteria in newly diagnosed axSpA patients with a symptom onset < 30 years. In addition, describe the extent of lesions on MRI of the sacroiliac joints (MRI-SI) in mNY positive (mNY+) patients with a symptom onset < 30 years.

Methods: This study involved newly diagnosed axSpA patients, age ≥18 years, from a Belgian (Be-Giant) cohort. Patients underwent diagnostic tests involving clinical examination, lab tests, and imaging assessment containing an X-SI and an MRI-SI. mNY criteria was assessed on X-SI. MRI-SI reads contained the assessment of inflammatory lesions according to the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring method and erosions, fatty lesions (FL), sclerosis, ankylosis using an adapted method of the SPARCC. Also, the ASAS definition of a positive MRI-SI was evaluated. T1-weighted and STIR images were viewed simultaneously. X-SI and MRI-SI were evaluated independently by 3 trained readers who were also blinded for clinical features. Imaging scores (X-SI grading according to the mNY criteria and mNY fulfillment, and MRI-SI lesion scores) were calculated as 2 out of 3 reader scores.

Results: In the 173 patients with available X-SI, the average age at symptom onset was 27.4 years old. In 114/173 (65.9%) patients, the symptom onset was below 30 years. Of those, 11 (9.6%) patients fulfilled the mNY criteria. Seven of the 11 (63.6%) patients that were mNY+ were male, which was slightly lower than in the mNY- patients (n=55; 53.4%). The presence of HLA-B27 was comparable between mNY+ and mNY- patients; 8 (72.7%) patients and 82 (79.6%) patients, respectively. Average X-SI grading in mNY+ patients was 4.7±1.3 (on a scale from 0-8) and in mNY negative (mNY-) patients (n=103) the average X-SI grading was 1.1±1.1.When looking at the MRI-SI assessment, 8/11 mNY+ patients (72.7%) and 60/103 mNY- patients (58.3%) had a positive MRI-SI (ASAS definition). The table shows the mean scores for MRI-SI lesions. In erosions, fatty lesions and ankylosis, either partial or complete ankylosis, there was a statistically significant difference (p< 0.05) between mNY+ and mNY- patients.

Conclusion: Patients with newly diagnosed axSpA and a symptom onset before 30 years infrequently fulfill the mNY criteria. A statistically significant difference in the presence of MRI-SI structural lesions was reported between mNY+ and mNY- patients. AxSpA patients with an early symptom onset have more erosions, fatty lesions and ankylosis on MRI when fulfilling the mNY criteria.


ACR 2019 – Table mNY 30y


Disclosure: M. de Hooge, None; A. De Craemer, None; T. Renson, None; P. Carron, None; L. Deroo, None; D. Elewaut, None; F. Van den Bosch, AbbVie, 5, 8, Abbvie, 5, 8, AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB, 5, 8, ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB, 5, 8, Bristol-Myers Squibb, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Janssen, 5, 8, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Sanofi, 5, 8, UCB, 5, 8.

To cite this abstract in AMA style:

de Hooge M, De Craemer A, Renson T, Carron P, Deroo L, Elewaut D, Van den Bosch F. AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/axspa-patients-with-symptom-onset-30-years-have-more-structural-lesions-on-mri-of-the-sacroiliac-joints-when-fulfilling-the-modified-new-york-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/axspa-patients-with-symptom-onset-30-years-have-more-structural-lesions-on-mri-of-the-sacroiliac-joints-when-fulfilling-the-modified-new-york-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology